Las Vegas, NV -- (SBWIRE) -- 12/12/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Cell Therapeutics Inc (NASDAQ:CTIC), ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Arca Biopharma Inc (NASDAQ:ABIO)
Cell Therapeutics Inc (NASDAQ:CTIC) managed to keep its fall at -1.69% on below -normal volume of 2.04M shares. The stock settled at $1.74 after floating in a range of $1.73 to $1.80. Its latest price has reached market capitalization of $225.93 million. Its 52-week range has been $0.97 to $2.17. Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer. The Company is concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need.
Has CTIC Found The Bottom and Ready To Move Up? Find Out Here
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) traded down on a volume of 3.24 million, lower than its standard daily volume. Shares have dropped-1.81% to $2.72. Over the last twelve months, the stock has gained 7.09% and faced a worst price of $1.83. ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.
Has IMUC Found The Bottom And Ready To Gain Momentum? Find Out Here
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) settled -6.79% lower at $3.02 on below -normal volume of 2M shares during the last trading day. The stock has its 12-month high at $10.17 and 52-week low price was $2.26. It traded in a range of $2.99 to $3.26 during the last trading day. Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections.
Will ACHN Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Arca Biopharma Inc (NASDAQ:ABIO) was up on high volume, trading at a volume of 1.93M versus its average daily volume of 1.59 million shares. At $1.52, the stock has attained market capitalization of 23.83 million. ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company's principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA's lead product candidate is Gencaro TM (bucindolol hydrochloride), a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF).
Will ABIO Continue To Move Higher? Find Out Here
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)